intervention,modality,indication,trial,study_id,endpoint,n_treated,responders_n,response_rate,esp,year,source,source_url,data_quality_score,notes
tisagenlecleucel (Kymriah),CAR-T,relapsed/refractory B-cell precursor ALL (pediatric/young adult),ELIANA (CCTL019B2202),NCT02435849,CR/CRi within 3 months after infusion,63,52,0.8253968253968254,1.2115384615384615,2017,FDA label (OpenFDA),https://api.fda.gov/drug/label.json?search=openfda.brand_name:Kymriah&limit=1,5,Label reports 63 infused patients with 52 (83%) achieving CR/CRi in Study 1.
axicabtagene ciloleucel (Yescarta),CAR-T,relapsed/refractory large B-cell lymphoma,ZUMA-1,NCT02348216,complete remission (CR) rate,101,52,0.5148514851485149,1.9423076923076923,2017,FDA label (OpenFDA),https://api.fda.gov/drug/label.json?search=openfda.brand_name:Yescarta&limit=1,5,Label reports N=101 with CR rate 52 (51%) in ZUMA-1.
onasemnogene abeparvovec (Zolgensma),gene therapy,"SMA type 1 (bi-allelic SMN1 deletion, symptom onset <6 months)",Study 1,NCT03306277,event-free survival (alive without permanent ventilation) at 14 months,21,19,0.9047619047619048,1.105263157894737,2019,FDA label (OpenFDA),https://api.fda.gov/drug/label.json?search=openfda.brand_name:Zolgensma&limit=1,5,Label reports 19 of 21 patients alive without permanent ventilation at 14 months.
voretigene neparvovec (Luxturna),gene therapy,RPE65 mutation-associated retinal dystrophy,Study 2,NCT00999609,MLMT score change >=2 at Year 1 (both eyes),21,11,0.5238095238095238,1.9090909090909092,2017,FDA label (OpenFDA),https://api.fda.gov/drug/label.json?search=openfda.brand_name:Luxturna&limit=1,5,Label reports 11 of 21 (52%) with MLMT score change >=2 at Year 1.
